OPN and αvβ3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma.
Expressions of OPN and αvβ3 are associated with a poor prognosis in many malignancies. However, their relationship in hepatocellular carcinoma remains unclear. We systematically collected hepatocellular carcinoma tissue samples from 305 patients over 3 years, and analyzed the status of OPN and αvβ3 in hepatocellular carcinoma and correlate expression with patient disease status and survival outcome. Our study results indicated that OPN and αvβ3 are expressed at significantly higher rates in hepatocellular carcinoma compared with adjacent non-tumorous tissue (69.5% vs 18.4%, p<0.01 and 77.4% vs 21.6%, p<0.01, respectively). Both OPN and αvβ3 expression levels are associated with poor prognostic factors, including tumor size, capsular invasion, tumor thrombus of the portal vein, metastasis of the lymph node and clinical staging. Patients expressing OPN and αvβ3 had significantly shorter survival compared with patients negative for protein expression (p<0.01). Multivariate analysis also showed that both OPN and αvβ3 expression are independent prognostic factors for poorer survival in hepatocellular carcinoma. By this study, we conclude that OPN and αvβ3 are negative prognostic predictors in patients with hepatocellular carcinoma. The expressions of both OPN and αvβ3 are associated with worse survival outcome.
Department of Pathology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Yi
Y
Jin
Department of Pathology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Jian-ning
JN
Chen
Department of Pathology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Zhi-ying
ZY
Feng
Department of Pathology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Zhi-gang
ZG
Zhang
Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Wen-zhe
WZ
Fan
Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Yu
Y
Wang
Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Jia-ping
JP
Li
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D053495:Osteopontin / Q000378:metabolism*; D011379:Prognosis; D015996:Survival Rate; D055815:Young Adult
D014408:Biomarkers, Tumor; D039302:Integrin alphaVbeta3; D053495:Osteopontin